8/4/2022 7:31:26 AM
Bio-Techne To Pay Dividend Of $0.32, Payable Aug. 29, Record Aug.15
8/4/2022 7:23:15 AM
Amended: Bio-Teche CEO Chuck Kummet To Retire, Effective June 30, 2024
8/4/2022 6:52:06 AM
Bio-Techne Q4 GAAP EPS $1.51; Adj EPS $2.05
7/6/2022 7:14:11 AM
Bio-Techne Launches CE-IVD RNAscope ISH Probe High Risk HPV Assay For Head And Neck Cancer
7/5/2022 7:05:41 AM
Bio-Techne Corp. Says Completes Namocell Acquisition
6/22/2022 7:01:25 AM
Bio-Techne Agrees To Acquire Namocell; Deal To Close On Q1 Of 2023
5/12/2022 7:10:48 AM
Bio-Techne And Nonagen Bioscience Announce Supply Agreement For Nonagen's Oncuria® Bladder Cancer Test
5/4/2022 6:38:35 AM
Bio-Techne Q3 GAAP EPS $1.48; Adj EPS $2.14
2/22/2022 7:12:00 AM
Bio-Techne Announces Agreement With Thermo Fisher Scientific For Exotru Kidney Transplant Rejection Assay
2/14/2022 7:12:21 AM
Bio-Techne Publishes Data Showing Exodx Prostate Test Correlation With Post-Prostatectomy Pathology Outcomes
2/1/2022 6:33:32 AM
Bio-Techne To Pay Dividend Of $0.32/shr; To Repurchase Of Up To $400 Mln Of Common Stock